MORRISTOWN, N.J., Feb. 28 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage, biopharmaceutical company, announced that Navaneetha K. Rao, Vice President Clinical Research and Development, is scheduled to present at Cambridge Healthtech Institute's 14th International Molecular Medicine Tri-Conference on March 1st at 4:15 p.m. PST at the Mascone North Convention Center in San Francisco. Dr. Rao will discuss Addressing Safety Concerns of Clinical Trials Conducted in India.
Navaneetha Rao is the Vice President of Clinical Research and Development for Vicus Therapeutics. Previously, Dr. Rao was the Head of RCRS, the full service CRO arm of Reliance Life Sciences, a new millennium initiative of the India based Reliance Group. Before joining Reliance, Dr. Rao was at Cato Research Limited. During his tenure at Cato Research, Dr. Rao served in multiple capacities, most recently as Associate Director of Clinical Development. Before joining Cato Research, Dr. Rao was Post Doctoral Research Fellow at Brigham and Women's Hospital, Harvard Medical School. Dr. Rao Received his B.Sc., from NDRI, India; his M.S., from Virginia Tech; and his Sc.D., from Harvard University.
About Vicus Therapeutics
Vicus Therapeutics is a privately-held, clinical-stage biopharmaceutical company located in Morristown, NJ, developing novel strategic approaches to the treatment of cancer supportive care indications. Vicus's lead program, VT-122, is in Phase II clinical trial for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has two preclinical programs for the treatment of oral mucositis and cancer fatigue. Vicus leverages its proprietary science to design and screen two-drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus's development programs are powered by its network of leading clinical investigators in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus's product candidates.
Website: http://www.vicustherapeutics.com
Vicus Therapeutics, LLCCONTACT: investors, John Maki, President and CEO, Vicus Therapeutics, LLC,+1-973-285-3175, or media, Tina Posterli of Rx Communications Group, LLC,+1-917-322-2565, for Vicus Therapeutics, LLC
Web site: http://www.vicustherapeutics.com//
